头颈部鳞状细胞癌中淋巴结检出数目的预后价值:一项系统综述
该系统综述检索PubMed和Embase截至2018年6月30日的文献,评估颈清扫淋巴结检出数目(NY)对头颈部鳞状细胞癌(HNSCC)患者总生存(OS)的预后价值。共纳入15篇文献,其中5项研究显示NY≥18枚较<18枚者生存显著改善,3项研究显示每多检出1枚淋巴结生存改善。作者认为NY(最常以≥18枚描述)与OS改善相关,可作为预后因素和医疗质量标志物。
要点
- 颈清扫淋巴结检出数目≥18枚与头颈部鳞状细胞癌患者总生存改善相关。
- 7项比较NY≥18 vs <18的研究中5项显示NY≥18组生存显著改善。
- 每额外检出1枚淋巴结与生存改善相关(3项研究)。
核心结论
- 颈清扫标本中淋巴结检出数目增加(最常描述为≥18枚)与头颈部鳞状细胞癌患者总生存改善相关,可作为预后因素和医疗质量标志物。
研究设计与样本
- 系统综述检索PubMed和Embase截至2018年6月30日的全部文献,筛选以淋巴结检出数目为预后因素、总生存为结局的头颈部鳞状细胞癌患者数据。
- 采用Quality In Prognosis Studies工具评估偏倚风险。
- 共筛选823篇文献,最终纳入15篇进行分析。
主要发现
- 7项比较淋巴结检出数目≥18枚 vs <18枚作为预后因素的研究中,5项显示≥18枚组生存显著改善。
- 6项研究使用其他截断值,3项研究报告每额外检出1枚淋巴结生存改善。
关键数值与推荐
- 淋巴结检出数目≥18枚是最常报告的预后截断值,与总生存改善相关。
- 每额外检出1枚淋巴结与生存改善相关(3项研究)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Literature analysis on the prognostic factor of the nodal yield (NY) in neck dissections (NDs), which in general surgical oncology is a strong prognosticator and quality-of-care marker. METHODS: We performed a systematic review of all PubMed and Embase publications until June 30, 2018 screening for data on NY as prognosticator and overall survival (OS) as outcome in patients with head and neck squamous cell carcinoma (HNSCC). Risk for bias was asserted by application of the Quality In Prognosis Studies tool. RESULTS: Of the 823 screened publications, 15 were included in this analysis. Five out of seven that compared NY ≥18 vs <18 as prognosticator, showed significantly improved survival if NY ≥18. Six studies used other cutoffs and three reported improved survival with each additionally harvested lymph node. CONCLUSION: Increased NY in ND specimen for HNSCC, most commonly described as ≥18 lymph nodes, is associated with improved OS and could be used as a prognosticator and quality-of-care marker.
引用
- de Kort WWB, Maas SLN, Van Es RJJ, et al. Prognostic value of the nodal yield in head and neck squamous cell carcinoma: A systematic review. Head Neck. 2019. PMID: 30969454. doi:10.1002/hed.25764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。